Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in statin-resistant familial hypercholesterolemia
NCT06231459Phase 4Completed
- Sponsor
- ISSSTE
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of evolocumab in familial hypercholesterolemia (FH), sponsored by ISSSTE. Primary endpoint: Serum lipid levels at 6 months. Started Jan 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT06231459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231459.